The global market size for cancer biomarkers is estimated to worth USD 14.3 billion in 2019 and estimated to be growing at a CAGR of 11.56%, to reach USD 24.8 billion by 2024.
In order to sustain their market shares, top players are constantly focusing on new product developments and improving their existing products to augment their product portfolios.
Biomarkers are chemical, physical or biological parameters that can be used to specify disease states. Oncology biomarkers offer high speed, non-invasive cancer diagnosis and deem to improve cancer detection and screening. The global cancer biomarkers market is consolidated in nature at the top.
Increasing knowledge over the utilization of biomarkers in the biotechnology field is considered to be a major factor fueling the demand of the market. A rise in the number of patients with various cancer diseases is fueling the growth of the market. Cancer biomarkers have an immense role in diagnosing cancer diseases where it is quite appropriate in screening and detection of cancer cells in various parts of the body. The aforementioned factor is greatly influencing the growth rate of this market. Also, growing support from the government through investments is ascribed to bolster the demand of the market to the extent.
However, fluctuations in the prices of the final products are limiting the demand of the market. These equipment require huge amounts for installation and maintenance which is also an attribute hindering the growth rate of the cancer biomarkers market. Lack of professionals in following the procedures due to less training programs is challenging the market developers.
Growth opportunities for the market lie in the increasing focus on developing innovative products with the latest technology. Furthermore, the rising prevalence of minimally invasive or non-invasive surgeries across the world is impacting the growth of the market towards positive. Increasing spending on healthcare especially in urban areas is leveling up the growth rate of the market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 - 2024 |
|
Segments Covered |
By Disease, Services, Type, Application, Profiling technologies, Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Abbott Laboratories, Agendia Bv, Biocurex Inc, Biomerieux S.A., Biomoda Inc, Astellas Pharma Us Inc, Correlogic Systems Inc, Beckman Coulter Inc, Becton, Dickinson And Company, Clarient Inc, Diadexus Inc, Ambrilia Biopharma, Affymetrix Inc and Aureon Laboratories Inc. |
This research report on Global Cancer Biomarkers Market has been segmented and sub-segmented into the following categories and analysed market size and forecast for each segment until 2024.
Cancer Biomarkers Market - By Disease
On the basis of disease, although every segment shares are going simultaneously, the prostate cancer disease segment is leading with dominant shares of the market. Increasing awareness over the availability of treatment procedures among individuals is promoting the growth of this market.
Cancer Biomarkers Market - By Services
On the basis of services, the Sample protection service type is holding prominent shares of the market. A rise in the constructional activities of healthcare centers globally is ascribed to bolster the growth of the market.
Cancer Biomarkers Market - By Application
On the basis of application, the Risk assessment application category is having the highest growth rate from the past few years with the increasing demand for early diagnosis.
Cancer Biomarkers Market - By Type
On the basis of type, Protein biomarkers type is holding dominant shares of the market. Growing priority for effective diagnosis of diseases in order to achieve better outcomes is lavishing the demand of the cancer biomarkers market.
Cancer Biomarkers Market - By Profiling Technologies
On the basis of profiling technologies, Omics technologies are witnessed in holding largest shares of the market. The emergence of advanced technologies and the introduction of new devices that are simple and convenient for users is likely to outshine the growth of this market.
Regional Analysis:
Asia-Pacific market is poised to record the highest growth rate in the forecast period due to the supporting government funding for cancer biomarker research, increasing prevalence of cancer, rising demand for advanced healthcare facilities in developing economies such as India and China, growing number of clinical trials, and rising focus of international players in emerging markets.
Top companies in the Cancer Biomarkers Market
Some of the major players operating in this market are Abbott Laboratories, Agendia Bv, Biocurex Inc, Biomerieux S.A., Biomoda Inc, Astellas Pharma Us Inc, Correlogic Systems Inc, Beckman Coulter Inc, Becton, Dickinson And Company, Clarient Inc, Diadexus Inc, Ambrilia Biopharma, Affymetrix Inc and Aureon Laboratories Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Disease
5.1.1 Introduction
5.1.2 Prostate Cancer
5.1.3 Breast Cancer
5.1.4 Lung Cancer
5.1.5 Colorectal Cancer
5.1.6 Cervical Cancer
5.1.7 Other Cancers
5.1.8 Y-o-Y Growth Analysis, By Disease
5.1.9 Market Attractiveness Analysis, By Disease
5.1.10 Market Share Analysis, By Disease
5.2 Services
5.2.1 Introduction
5.2.2 Sample Preparation
5.2.3 Assay development
5.2.4 Biomarkers validation and testing
5.2.5 Y-o-Y Growth Analysis, By Services
5.2.6 Market Attractiveness Analysis, By Services
5.2.7 Market Share Analysis, By Services
5.3 Application
5.3.1 Introduction
5.3.2 Risk Assessment
5.3.3 Development of molecular diagnostics
5.3.4 Disease diagnosis
5.3.5 Drug discovery
5.3.6 Development and Drug formulation
5.3.7 Y-o-Y Growth Analysis, By Application
5.3.8 Market Attractiveness Analysis, By Application
5.3.9 Market Share Analysis, By Application
5.4 Type
5.4.1 Introduction
5.4.2 Protein Biomarkers
5.4.3 Genetic biomarkers
5.4.4 genetic biomarkers
5.4.7 Y-o-Y Growth Analysis, By Type
5.4.8 Market Attractiveness Analysis, By Type
5.4.9 Market Share Analysis, By Type
5.5 Profiling Technologies
5.5.1 Omics technologies
5.5.1.1 Genomics
5.5.1.2 Proteomics
5.5.1.3 Metabolomics
5.5.1.4 Transcriptomics
5.5.1.5 Pharmacogenomics
5.5.2 Imaging technologies
5.5.3 Immunoassays
5.5.4 Cytogenetics
5.5.5 Bioinformatics
5.5.6 IVD multivariate index assays
5.5.7 Y-o-Y Growth Analysis, By Profiling Technologies
5.5.8 Market Attractiveness Analysis, By Profiling Technologies
5.5.9 Market Share Analysis, By Profiling Technologies
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Disease
6.1.3.3 By Services
6.1.3.4 By Application
6.1.3.5 By Type
6.1.3.6 Profiling Technologies
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Disease
6.1.4.3 By Services
6.1.4.4 By Application
6.1.4.5 By Type
6.1.4.6 Profiling Technologies
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Disease
6.1.5.3 By Services
6.1.5.4 By Application
6.1.5.5 By Type
6.1.5.6 Profiling Technologies
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Agendia Bv
8.3 Biocurex Inc
8.4 Biomerieux S.A.
8.5 Biomoda Inc
8.6 Astellas Pharma Us Inc
8.7 Correlogic Systems Inc
8.8 Beckman Coulter Inc
8.9 Becton
8.10 Dickinson And Company
8.11 Clarient Inc
8.12 Diadexus Inc
8.13 Ambrilia Biopharma
8.14 Affymetrix Inc
8.15 Aureon Laboratories Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
